Most Important Messages Since General Overview, see link below for G.O.
Message 5248323
This a collection of various posts that help explain Sanguine and Dr. Drees.
Don't forget the Information thread.
Thanks To All The Contributors,the Doctor's, and everyone else.
Yes sir, very familiar. As I have been keeping up with all the excellent information regarding SGNC on the 2 SGNC threads I am very familiar with Dr. Drees having already spent many years developing a PFC product while he was the head of Alpha. This first gen. product was already given FDA approval. It was already tested on approximately 13,000 humans.
I am very familiar with the fact that this second generation PHER-02 product is a slightly enhanced version of the previously FDA approved first gen. product that was already tested on 13,000 humans.
Dr. Drees is extremely familiar with numbers you pointed out also.
He is also extremely familiar with what is needed to get a PFC product through the FDA approval process. He is also very familiar with using a PFC product on humans. A very good man to have on our side!
I sure am glad that I am not investing in a first generation product that has to go through 16-20 years of development and has never been tried on humans. This 2nd generation PHER-02 from SGNC that I am investing in is an enhanced version of the first gen. product that has already beaten the 5000-1 odds that you mention - it was already tested on 13,000 humans. It also beat the 5-1 odds you mention - it was FDA approved.
So thank you for reminding me of what to look out for if I happen to invest in a different biotech company that has not had any generation of its product tested on humans, much less received FDA approval.
Cheers
Mike
Questions and answers from Dr. Drees
SGNC no longer uses egg phospholipid as a surfactant. It caused mild allergic reactions in a few of our clinic..
SGNC has been fully reporting since 1993 and plan on being on NASDAQ when we have liquid assets of $8,000,000 + to qualify.
questions answered by DR Drees.
prospector
No change in business plan. We plan the U.S. and Europe testing / marketing programs to be simultaneous..We have several prospective partners in the works.
Prospector ( as per Dr Drees answers)
Answers to your questions as per Dr Drees
1. Flousol had slight allergic reactions in clinical trail patients, which went away when mild steroids were given to the few patients affected. The new formulation has a tighter bond in the emulsion, because the new surfactant is also fluoronated to improve emulsion stability so that he finished emulsion does not have to be frozen, as did fluosol.
2. Time table for Phase 1 (19990 , Phase 2 (2000) Phase 3 (2001).
3. The dosage will vary with the usage,i.e. angioplasty (400 ml ), transfusion (500 ml x 4) etc.
4. We will branch out to the 150 areas we know about, and more.
5. Most likely side affects of PHER-02 is a slight allergic reaction and it is not dose dependant.
Prospector
Sanguine Corp. (Pasadena, LA County) announced on June 3rd,
1996, that it has signed a contract with the Utah-based Travis Capital
Inc. to assist Sanguine in raising $7 million to fund the development of its
proprietary red blood cell supplement, PHER-O2. Sanguine was founded
in 1991 by the former CEO of Alpha Therapeutic, Thomas Drees. Since
then, it has been developing PHER-O2 for use in medical procedures
such as transfusions, transplant organ-perfusion, open heart surgery,
imaging and angioplasty.
Sanguine believes that PHER-O2 has numerous advantages over
human blood. In its press release, the company mentioned that PHER-02
carries no blood-borne diseases such as HIV and hepatitis; has the
ability to carry three to four times the oxygen of human blood per unit
volume; will match all blood types; is amenable to mass production; has
a three-year shelf life; and can be stored at room temperature. For more
information, contact the company at 818-405-0079.
1. Any word on CBS yet? TALKING WITH CBS NOW
2. Sanguine has had a working relationship with Battelle since 1994. BATTELLE - SANGUINE SINCE 1994 HAS COMPLETED R&D ON SGNC'S
Can he elaborate on what they had done?
BATTELLE - SANGUINE SINCE 1994 HAS COMPLETED R&D ON SGNC'S FORMULAS PLUS DEVELOPED 8 NEW FORMULS FROM WHICH TO DEVELOPE THE BEST ONE.. FDA ANIMAL TRIALS ARE NEXT STEP IN BATTELLES OUTSTANDING ANIMAL FACILITIES
3. Has anyone done the (Gross Rat) test yet?
WE HAVE NOT DONE THE GROSS RAT TEST, BUT SUSPECT THAT BATTELLE HAS.
4. If animal testing has begun, what animal's are they using?
SOON,,, MICE,, RATS, GUINEA PIGS,, DOGS..
DISCUSSING $30,000,000 FUNDING BUT NOT SIGNED..
3,800,000 SHARES IN FLOAT.
Prospector
Reproductivity Toxicity (Rats) Fluosol-R
Doses given in the reproductive studies were substantially greater than the human dose. Fluosol was administered to females in the reproductive studies as daily dose of 2.5, 5 or 10 mL/Kg/day for periods of 11,21, , or 25 days before, during, and after the gestation period. The minimum total dose was 27.5 mL/Kg (2.5 mL/Kg/day for 11 days), which is appoximately 5 times greater than the maximum human dose of 5.7 mL/Kg used in the human clinical studies of Fluosol_r.
Fluosol-r had no effect on the contraction of the isolated rat uterus between the 8th and 19th day of gestation. There was no effect upon fertility and reproductive performance in rats. The drug was administered at doses of 2.5, 5, or 10 mL/Kg/week for nine weeks to males and 2.5, 5, and 10 mL/Kg/day for 21 days, commencing 14 days before mating and ending on day 7 of pregnancy in females. The lack of embryotocity and teratogencity of the pregnant females at 20 days gestation. A second study was conducted with Fluosol-r given at 2.5, 5 and 10 mL/Kg//day to pregnant rats from gestation days 7 to 17; there were no embryotixic or teratogenic effects.
Prospector
Howdy there Just got off the Phone with the Dr,,
He said testing is under way at Battelle,,
1. First they( FDA) will wade through the Paper work and make sure all the i's are dotted and the t's are crossed... this will take a little while.
2. The they will check out PHER-02 in the lab without the animals and make sure it carries oxygen,, and the things it's supposed to do.
3. Then they will start the animal testing,, somethin about safety,, make sure the can still be reproductive,, and carry on normal life functions.
4. Then they will put them under Stress and see what happens to them ,, like induce heart attacks ,, sickness and normal everyday parental situations (like raisin kids)hhahahaha...
Prospector...
Don't forget that Batelle has an OPEN contract with SGNC should they
decide that someday they want to make a deal with SGNC for some kind
of royalties or something..
very interesting that they wanted that don't you think?
jim
Here's an interesting comparison from the following link:
battelle.org
At Battelle ...
Under the direction of Frederick A. Dombrose, Ph.D., the Consortium has an independent Scientific Advisory Board that provides strategic assessment, reviews proposals for financial support, and facilitates an expanded scientific network. Projects favorably considered for funding by the Consortium focus on innovative methods to eradicate non-enveloped viruses (e.g., Hepatitis A virus, Parvovirus, Vaccinia, and SV40) in whole human plasma, without affecting the functionality of the plasma.
Sound like a familiar equation???
Ph.D (Dombrose) + Scientific Advisory Board + scientific lab (Battelle) = solution to scientific/medical problem (eradicate blood viruses).
Ph.D (Drees) + Scientific Advisory Board + scientific lab (Alpha/Green Cross) = solution to scientific/medical problem (Fluosol-DA)
Ph.D (Drees) + Scientific Advisory Board + scientific lab (Battelle) = solution to scientific/medical problem (PHER-02)
Cheers
Mike
TO ALL::
been talking behind the scenes with someone that actually IS in the professional business of R&D for biotech developments..
I asked them to call Dr Drees and here is the email I just received..
THANKYOU to our anonymous helper!!
---------
Dr.Drees was pretty candid about his need for a partner in terms of funding the manufacturing and clinical trials. He told me he did shop it around to some of the big pharma companies when it was still just an idea. Their response to him was " come back when you get FDA approval". We discussed their response and felt that some good results in animal trials would go a long ways in getting them to take a second look. Most companies would want to see data on paper before they will sink money into something like this.
Other issues which could effect partnering is OTC/BB listing. That is why I personally think a buyout would be more likely.
They did receive an FDA aproval on the primary compound of which this PHER-fluorocarbon is secondary. However, the rights to that compound are owned by three scientists that discovered it. His PHER-fluorocarbon is different enough to allow for a patent, yet similar enough to make him feel that the behavior will be similar when they put it into animals. This will not be known until it actually happens and results can be assessed. There will probably be some differences and this will cause some minor delays and restructuring of experimental design. The individual that worked on the experiments for the original compound is also planning out these exp.'s, so
as to give them a better idea of what parameters to use and should expedite results and should also decrease costs.( someone who knows what they are doing will get it right faster and therefore save money).
We also discussed the possibility of primate tests. He did not have to use primates when getting approval for the original compound, but agreed that sometimes the FDA will make it mandatory. In fact, I have heard recently, they usually make you do a primate study for safety.Dr. Drees admitted that he may very well find that the FDA requires him to do so.
We also talked of the difference between chlor-fluorocarbons and
pher-fluorocarbons. I brought this up because the public has a negative view of the word" fluorocarbons" as they are the group of chemicals that are thought to play a part in "ozone hole phenomena" and I believe refridgeration coolants. He actually thought that my bringing that point up was very good as he must be careful to separate the two classes of fluorocarbons.They are different, but the very word"fluorocarbon" strikes terror in the hearts of many environmentalists ( wanna-be's).
Also, the emulsion does not contain anything that could be covered by anyone else's patent.
-------
I'll be getting more info from this person from time to time and I have been given permission to graciously share this info with you all!
not that this all means that we're going to be jumping up and down soon ... but rather that the long term future for SGNC looks bright.
jim
Jimb conferance call on 7/8/98 with Dr. Drees
Message 5210541
Mike Ankley spent a lot of time gathering this information on patents. Thank you. Some of abstracts give good insight as what all the possible uses for this product can be.
Dr. Drees: coinventor of U.S. patents
Message 5237223
Message 5237230
Message 5237234
Green Cross assigned U.S. patents
Message 5237245
Message 5237273
Message 5237276
Message 5237279
Message 5237283
Message 5237287
Message 5237290
Message 5237291
Message 5237296
Message 5237298
Message 5237302
Message 5237305
Message 5237309
Message 5237311
Message 5237313
Message 5237315
Message 5237316
Message 5237317
Message 5237319
Message 5237321
U.S. patents for Perfluorodecalin; Fluosol
Message 5237256
Message 5237265
Hillel Laks,M.D. (Sanguine Advisory Board) Information presented by Mike Ankley.
Read below how this Doctor is Director of 6 programs at UCLA Department of Surgery, Ranked in list of country's best Doctors, Operates on Tiger Woods dad, Slyvestor Stallone grateful to Doctor , Saves lives of 3 newborns. Great work Mike.
Message 5240874
Message 5240894
Message 5240902
Message 5240943
Message 5240959
Message 5240974
Message 5240983
Message 5240993
Message 5241005
Message 5241018
Message 5241168 |
